About US
Contact us
-
AstraZeneca's COVID-19 vaccine production partner Emergent not likely to suffer if trial hold sticks: analystsAstraZeneca was humming right along with its partnered COVID-19 vaccine with the University of Oxford before a sudden trial hold threw its plans into disarray. So what does that uncertainty mean for2020/9/11
-
Novartis, Roche fined $526M in France for alleged Lucentis marketing misstepsSix years ago, the French Competition Authorityraidedthe local offices of Roche and Novartis in search of evidence of missteps in the way the companies were marketing Lucentis for age-related macular2020/9/10
-
Pfizer, BioNTech near Euro supply deal for up to 300M doses of COVID-19 vaccineIn the hunt for a COVID-19 vaccine, no front-runner is moving as quickly as Pfizer and BioNTech's mRNA-based shot, which is scoping an October regulatory review. Despite some technicalconcerns about2020/9/10
-
Catalent injects $130M into Maryland cell and gene therapy site drafted into COVID-19 vaccine huntNew Jersey contract manufacturer Catalent has been right in the mix in the COVID-19 response effort, signing pacts to help produce frontrunners in the vaccine hunt. Now, the company is fleshing out a2020/9/9
-
Takeda's selloff spree continues with $562M deal with Germany's CheplapharmWith last month’s $2.3 billion Japanese consumer health sale to Blackstone Group, Takeda has arguably achieved its $10 billion divestment goal. But the Japanese pharma is showing no sign of stopping2020/9/9
-
Mylan boosts Euro portfolio with $756M rights deal for Aspen's injectable thrombosis medsMylan's planned megamerger with Pfizer's Upjohn generics unit has had a rocky road to approval, with the novel coronavirus pandemic snagging regulatory review. Despite the delay, Mylan isn't twiddlin2020/9/8
-
CSL plots millions of doses of COVID-19 vaccine shots, including AstraZeneca's, for Aussie governmentLooking to secure enough doses of a COVID-19 vaccine frontrunner for its residents, the Australian governmentsigned an expansive supply deal with British drugmaker AstraZeneca last month. The Aussies2020/9/8
-
Biocon, Mylan's Lantus copy; Samsung rides COVID-19 demand; Adlai Nortye's C roundMylan and Biocon will launch Semglee, their biosimilar of Sanofi's Lantus, at a discount. Samsung Biologics' $2 billion "Super Plant" expansion is the result of increased demand partly due to COVID-12020/9/7
-
Amgen wriggles out of state bill on rat poisons, says it prefers its rodent-killing methodsWith a bill passed this week, California legislators and environmentalists cast a spotlight on the use of industrial rodent poisons that are killing off native wildlife. But local drugmaker Amgen wan2020/9/7
-
Biotech CEOs pen standards for coronavirus trials, data disclosures amid FDA reputation crisisAmiddoubts about the FDA’sdecision-makingprocessduring the pandemic,biotechCEOson the front lines of research arelaying outtheir approachand asking“all parties”involved in the process to adhere to hi2020/9/4